Announcing the nomination of DPTX3496, the second #cmod development candidate that targets the oncogenic driver function of beta catenin in Wnt-driven cancers. IND-enabling studies are progressing and IND filing is planned for the second half of the year.

Our lab's latest News & Views in @NatureChemistry analyzes key findings from Thody et al: physicochemical properties, not structure, drive small molecule partitioning into biomolecular condensates. Important implications for drug development! @kriwacki https://t.co/S9LeXViZ6q

Great coverage in @ThePharmaLetter about a major milestone for Dewpoint – the nomination of our first development candidate, DPTX3186, as a potential therapeutic agent for the treatment of Wnt-driven cancers. Read the article:

Another major milestone for Dewpoint: the nomination of DPTX3186 as the first condensate modulating development candidate, for the treatment of Wnt-driven cancers. DPTX3186 c-mod inhibits the function of a historically ‘undruggable’ target – beta catenin.

Our next Kitchen Table Talk is tomorrow, October 30, with Dragomir Milovanovic, Principal Investigator - Molecular Neuroscience, German Center for Neurodegenerative Diseases. Join us to learn about “Condensate biology at the synapse”. Register here:

Why is Dewpoint Therapeutics One to Watch? Revolutionary #condensate science with applicability across therapeutic areas, an #AI-powered state-of-the-art platform, unrivaled expertise, and a culture that nourishes growth and innovation.

Dr. @JesseLai will present on October 9 at the Society for Neuroscience’s Neuroscience 2024 conference. Join him to find out how a #condensate modulating drug reverses markers of #ALS pathology, by targeting a #condensatopathy shared by ~97% of patients. https://t.co/Lp0nghAu6P

Don't miss @DragMilovanovic 's upcoming Kitchen Table Talk, on October 30th! Registration is open at

Today we announced multiple patent applications on novel composition of matter for the treatment of ALS, “a significant leap forward in our mission to redefine the treatment of diseases deemed intractable or difficult to treat” Read the Press Release: https://t.co/o5Uj28kUFV

Our newest perspective discussing opportunities in targeting #condensates as a new class of antivirals is now in press @JMolBiol with @dewpoint_tx

Read our latest @JMolBiol perspective by @ewmartin, Christiane Iserman, Balaji Olety, @DiaMitrea & @IsaacAKlein reviewing the role of #condensates in the viral replication cycle and discussing novel strategies to target them for novel antiviral therapies:

We are pleased to share Dewpoint CSO @IsaacAKlein’s @DDWJournal podcast about the intersection of #condensate science and therapeutic development. Isaac brings his unique perspective as a physician-scientist to solving complex biological puzzles and advancing drug discovery.

At last week’s annual @GeneticsSociety meeting, Dewpoint scientist @Ruoyu_Tian shared our advances in identifying the role of #condensates in common diseases and their related traits. #ASHG23 See the Reviewers’ Choice poster for more details: https://t.co/oQ4VrdQLfL

Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Advance Oncology Pipeline - Read more: https://t.co/MuDiRtaO71

In the last 5 years, Dewpoint has made huge progress evolving and applying the science of condensates towards therapeutic discovery. Read our latest article to hear more from our CSO @IsaacAKlein https://t.co/e89VsAZ3OY

Dewpoint co-founder @youngricka, board member @BarzilayRegina, head of Cancer Biology @BoijaAnn & team published in @nchembio how deep learning predicts specific partitioning of small molecules in #condensates with distinct chemical environments:

Congratulations team on this exciting and valuable resource, demonstrating the broad implications of aberrant condensation in oncology!

Published today in @NatureComms - our efforts to better understand the prevalence of biomolecular condensate formation amongst fusion oncoproteins found in a range of diverse cancers. https://t.co/drxIN2tRMU

See a promising example of a condensate-modifying drug that inhibits tumor growth in the recent @Nature paper from @Conrad_Lab showing FSP1 inhibition via relocalization to condensates, which induces ferroptosis in cancer cells. https://t.co/9NOaj8LzCJ

In a recent @Pharmafocus interview, Dewpoint CEO Ameet Nathwani shares his thoughts on the current landscape of diabetes therapies. Read to learn how #condensates play a role in disease progression and may be targeted with a new generation of therapeutics: https://t.co/H3LWJRcpNi